We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Amylyx Pharmaceuticals Inc (AMLX) USD0.0001

Sell:$15.30 Buy:$15.34 Change: $0.09 (0.60%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
Change: $0.09 (0.60%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
Change: $0.09 (0.60%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX003 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). The Company is developing AMX0035 for other neurodegenerative diseases by leveraging knowledge and relationships in the neurodegenerative space. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.

Contact details

United States
+1 (617) 6820917

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.01 billion
Shares in issue:
67.52 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Joshua Cohen
    Co-Chief Executive Officer, Director
  • Justin Klee
    Co-Chief Executive Officer, Director
  • James Frates
    Chief Financial Officer
  • Gina Mazzariello
    Chief Legal Officer and General Counsel
  • Margaret Olinger
    Chief Commercial Officer
  • Patrick Yeramian
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.